492 related articles for article (PubMed ID: 34121589)
1. Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens.
Zamagni E; Dhanasiri S; Ghale A; Moore A; Roussel M
Leuk Lymphoma; 2021 Oct; 62(10):2492-2501. PubMed ID: 34121589
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries.
Abildgaard N; Anttila P; Waage A; Rubin KH; Ørstavik S; Bent-Ennakhil N; Gavini F; Ma Y; Freilich J; Hansson M
Eur J Cancer; 2024 Apr; 201():113921. PubMed ID: 38377776
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
Lee JY; Park SS; Jeon YW; Shin SH; Yahng SA; Min CK;
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11907-11918. PubMed ID: 37418057
[TBL] [Abstract][Full Text] [Related]
4. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
Fonseca R; Usmani SZ; Mehra M; Slavcev M; He J; Cote S; Lam A; Ukropec J; Maiese EM; Nair S; Potluri R; Voorhees PM
BMC Cancer; 2020 Nov; 20(1):1087. PubMed ID: 33172403
[TBL] [Abstract][Full Text] [Related]
5. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.
Gordan LN; Tan CR; Vescio R; Ye JC; Schinke C; Medhekar R; Fu AZ; Lafeuille MH; Thompson-Leduc P; Khare V; Reitan J; Milkovich G; Kaila S; Davies F; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):55-63. PubMed ID: 37838502
[TBL] [Abstract][Full Text] [Related]
6. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Bumma N; Dhakal B; Fraser R; Estrada-Merly N; Anderson K; Freytes CO; Hildebrandt GC; Holmberg L; Krem MM; Lee C; Lekakis L; Lazarus HM; Mian H; Murthy HS; Nathan S; Nishihori T; Parrondo R; Patel SS; Solh M; Strouse C; Vesole DH; Kumar S; Qazilbash MH; Shah N; D'Souza A; Sidana S
Cancer; 2023 Jul; 129(14):2179-2191. PubMed ID: 37021929
[TBL] [Abstract][Full Text] [Related]
7. The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma.
Chen W; Liu A; Li L
Adv Ther; 2023 Feb; 40(2):705-717. PubMed ID: 36463561
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis.
Manier S; Dimopoulos M; Hulin C; Leleu X; Delforge M; Weisel K; Mouro J; Costa B; Sturniolo M; Facon T
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e297-e306.e1. PubMed ID: 37393121
[TBL] [Abstract][Full Text] [Related]
9. Treatment Pattern and Outcome of Newly Diagnosed Multiple Myeloma Patients in a Resource-Limited Setting.
Cheong CS; Tengku K Aziz TAH; Anuar NA; Bee PC; Chin EFM; Khairullah S; Liong CC; Zamri Y; Gan GG
Asian Pac J Cancer Prev; 2024 Feb; 25(2):595-601. PubMed ID: 38415546
[TBL] [Abstract][Full Text] [Related]
10. RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Chapman MA; Sive J; Ambrose J; Roddie C; Counsell N; Lach A; Abbasian M; Popat R; Cavenagh JD; Oakervee H; Streetly MJ; Schey S; Koh M; Willis F; Virchis AE; Crowe J; Quinn MF; Cook G; Crawley CR; Pratt G; Cook M; Braganza N; Adedayo T; Smith P; Clifton-Hadley L; Owen RG; Sonneveld P; Keats JJ; Herrero J; Yong K
Blood; 2018 Nov; 132(20):2154-2165. PubMed ID: 30181174
[TBL] [Abstract][Full Text] [Related]
11. Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect
Abonour R; Rifkin RM; Gasparetto C; Toomey K; Durie BGM; Hardin JW; Terebelo HR; Jagannath S; Narang M; Ailawadhi S; Omel JL; Lee HC; Srinivasan S; Kitali A; Agarwal A; Wagner L;
Br J Haematol; 2021 Apr; 193(1):93-100. PubMed ID: 33118614
[TBL] [Abstract][Full Text] [Related]
12. Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Richardson PG; Durie BG; Rosiñol L; Mateos MV; Dispenzieri A; Moreau P; Kumar S; Raje N; Munshi N; Laubach JP; O'Gorman P; O'Donnell E; Voorhees P; Facon T; Bladé J; Lonial S; Perrot A; Anderson KC
Haematologica; 2023 Nov; 108(11):2894-2912. PubMed ID: 37608773
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial.
Yokoyama A; Kada A; Saito AM; Sawamura M; Komeno T; Sunami K; Takezako N
Acta Med Okayama; 2019 Dec; 73(6):547-552. PubMed ID: 31871340
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain.
Lehne M; Kortüm KM; Ramasamy K; Zamagni E; d'Estrubé T; Zhuleku E; Hanna M; Shukla S; Ghiani M; Maywald U; Wilke T; Kellermann L; Perera S
Eur J Haematol; 2024 May; 112(5):701-713. PubMed ID: 38146208
[TBL] [Abstract][Full Text] [Related]
15. Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum.
Shimura Y; Shibayama H; Nakaya A; Yamamura R; Imada K; Kaneko H; Hanamoto H; Fuchida SI; Tanaka H; Kosugi S; Kiyota M; Matsui T; Kanda J; Iida M; Matsuda M; Uoshima N; Shibano M; Karasuno T; Hamada T; Ohta K; Ito T; Yagi H; Yoshihara S; Shimazaki C; Nomura S; Hino M; Takaori-Kondo A; Matsumura I; Kanakura Y; Kuroda J
Int J Hematol; 2023 Nov; 118(5):609-617. PubMed ID: 37668833
[TBL] [Abstract][Full Text] [Related]
16. Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".
Mele G; Di Renzo N; Cascavilla N; Carella AM; Guarini A; Mazza P; Melillo L; Pavone V; Tarantini G; Curci P; Falcone AP; Germano C; Mele A; Merchionne F; Palazzo G; Palumbo G; Quinto AM; Reddiconto G; Rossini B; Spina A; Sgherza N; Specchia G; Musto P; Pastore D
Leuk Lymphoma; 2023 Oct; 64(10):1715-1718. PubMed ID: 37417467
[No Abstract] [Full Text] [Related]
17. Lenalidomide maintenance in Myeloma - a goldilocks problem?
Ng Liet Hing M; Khot A
Leuk Lymphoma; 2023 Oct; 64(10):1611-1614. PubMed ID: 37671741
[No Abstract] [Full Text] [Related]
18. Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma.
Bici A; Pianko MJ; Nachar VR
Leuk Lymphoma; 2023 Feb; 64(2):407-414. PubMed ID: 36308285
[TBL] [Abstract][Full Text] [Related]
19. Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Jiménez-Ubieto A; Paiva B; Puig N; Cedena MT; Martínez-López J; Oriol A; Blanchard MJ; Ríos R; Martin J; Martínez R; Sureda A; Hernández MT; de la Rubia J; Krnisk I; Cabañas V; Palomera L; Sánchez-Pina JM; Bargay J; Mateos MV; Rosiñol L; Blade J; San Miguel J; Lahuerta JJ;
Blood; 2021 Nov; 138(19):1901-1905. PubMed ID: 34329372
[No Abstract] [Full Text] [Related]
20. Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis.
Hoff FW; Banerjee R; Khan AM; McCaughan G; Wang B; Wang X; Roose J; Anderson LD; Cowan AJ; Rajkumar SV; Kaur G
Blood Cancer J; 2024 Mar; 14(1):52. PubMed ID: 38519476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
